A Study of Ultra High Dose Diuretics to Treat Heart Failure

• Status: Enrolling by invitation
• Trial end date: 2024-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and effectiveness of ultrahigh dose diuretics compared to standard dose diuretics over 24 hours in patients with decompensated heart failure.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Bumetanide; Diuretics; Furosemide

Criteria

Inclusion Criteria:

• Diagnosis of decompensated heart failure receiving intravenous diuretics

• Ability to provide informed consent

Exclusion Criteria:

• Patients on home inotrope medications

• Patients with Chronic Kidney disease stage V and end stage renal failure on dialysis

• Patients lacking the capacity to consent for themselves

• Known pregnancy or breastfeeding mothers

• Complex congenital heart disease

• Allergy to furosemide or bumetanide

• Respiratory failure requiring non-invasive ventilation (CPAP/BiPAP) or invasive mechanical ventilatory support at the time of randomization

• Hypotension with systolic blood pressure <80 mm Hg at the time of randomization

• Acute coronary syndrome

• Sustained Ventricular tachycardia requiring treatment in the last 48 hours

• Patients weighing ≤ 40 kg